New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States
RAND Health Quarterly · 2025 · 13 (1)
DOI: 10.7249/rhq-13-01-03 ↗Kurz gefasst
Fachartikel in der Zeitschrift RAND Health Quarterly, 2025. Verfasst von Robert Bozick und 2 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref).
Abstract (Originalsprache)
Prescriptions made for GLP-1 agonists under various brand names (e.g., Ozempic, Wegovy) have more than tripled since 2020. However, research on their use and their side effects at the population level is in its infancy. This study presents descriptive findings from a 2025 survey fielded to a nationally representative sample of U.S. adults as part of RAND's American Life Panel that show prevalence rates of GLP-1 agonist use and side effects.
Zitieren
APA
Bozick, R., Donofry, S., & Rancaño, K. (2025). New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States. RAND Health Quarterly, 13(1). https://doi.org/10.7249/rhq-13-01-03
Vancouver
Bozick R, Donofry S, Rancaño K. New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States. RAND Health Quarterly. 2025;13(1). doi:10.7249/rhq-13-01-03
BibTeX
@article{Bozick2025,
author = {Bozick, Robert and Donofry, Shannon and Rancaño, Katherine},
title = {New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States},
journal = {RAND Health Quarterly},
year = {2025},
volume = {13},
number = {1},
doi = {10.7249/rhq-13-01-03}
}
EUVIMED